Cancer is the second known lethal disorder after coronary heart disease, characterized by the loss of control of cell growth leading to excessive proliferation and spread of cells. Different diagnostic tools and different protein or glycoprotein markers are available for diagnostic utility and prognosis of cancer in patients. Of these, some diagnostic markers are promising but some still need to be validated for their utility. In this study, we demonstrate the pathogenesis of different types of cancer, such as cancer of breast tissue, pancreatic tissue, ovary, prostate, lung tissue and colorectal tract and the utility of a panel of diagnostic markers for them.
TUMOURS are usually acknowledged by cells having abnormal growth, with the loss of controlled growth mechanism 1 . Tumours are classified into benign, in situ and malignant tumours. Malignant tumours have abnormal genetic expression and this expression depends on age, degree of cell differentiation, growth, invasion and metastatic potential as well as therapy responses 2 . In different cancer conditions, tumour cells produce a range of proteins that stimulate the growth of blood vessels into the tumour, thus allowing continuous growth to occur and may be responsible for invasive behaviour. Different carcinogens, proved to be responsible for carcinogenesis, do not cause tumours directly. There are a series of events that include initiation of transformation of cell (preneoplastic). After initial transformation, different factors (promoting agents) cause changes in genetic material (DNA) leading to development of neoplastic malignant tumour 3 . Apoptosis is one of the most extensively studied phenomena to understand the programmed cell death process in cancer conditions as it gives a clear vision into disease pathogenesis. Cancer is characterized by loss of equilibrium between cell division and apoptosis. p53 is a tumour suppressor gene which itself down-regulates in cancer and hence, reduced apoptosis of cancer cells 4 . Different tools for diagnosis of cancers are imaging procedures, including CT scan, nuclear scan, MRI, PET, ultrasound, X-ray and biopsy. However, due to affordability, screening of diagnostic makers has higher potential. For diagnosis of different types of cancer, there are several diagnostic biomarkers available. Of these, some are well established and some still need to be validated. In this study, we describe a panel of diagnostic markers for different types of cancer.
Head and neck carcinoma
There are several ways to classify the biomarker of head and neck cancer but few have shown positive results. In most cases, head and neck tumours can be distinguished when the disease shows symptoms. Epidermal growth factor receptor (EGFR), a member of the ErbB family of receptors, is an important therapeutic target, but a poor prognostic marker of head and neck squamous cell carcinoma (HNSCC). A comparative study was done using specific monoclonal antibodies, which recognized EGFR extracellular domain molecule, to know the impact of EGFR expression in HNSCCs patients' status. They carried out quantitative EGFR immunohistochemical analysis to get mean absorbance (MOD), staining index (SI), and quick score (QS). They reported that HNSCCs had a wide discrepancy in expression of EGFR (MOD, 0.2 to 66.0; SI, 0.3 to 97.0; QS, 0.01 to 69.9) with a comparatively strong, but nonlinear, relationship between MOD and SI (r = 0.79) 5 . Despite extensive studies on squamous cell carcinoma of head and neck (SCCHN), EGFR remains the only non-chemotherapeutic molecular target used by clinicians for clinical benefit 6 .
Brain cancer
Brain cancer begins with the transformation of normal brain cells to cancerous cells. Glioma is reported as a very common subgroup of brain tumours arising from glial cells. Apart from mechanical tools including CT scan, MRI, angiogram, X-ray, spinal tap and biopsy, some biomarkers are also reported for diagnosis of glioma that includes EGFR, which was found to be highly expressed or mutated in malignant condition. Activation of EGFR was also reported to block the development of new neurons and was linked with a remarkable increase in chemotaxis process in the presence of EGF 7 . YKL-40
is an important biomarker to check the response of radiation therapy and for prognosis in glioblastoma multiforme. YKL-40 was reported to be an independent marker of survival in glioblastoma patients, after considering several factors such as age of patients, performance status of brain and degree of re-section 8 . It was also suggested that it could be carcinogenic in brain cancer 8 . The expression of protein marker, glial fibrillary acidic protein (GFAP), was studied in serum of patients with brain tumour. It was found that the concentration of GFAP was directly proportional to the degree of glioblastoma and degree of tumour necrosis imaged using MRI 9 . It is reported that inactive Ephrin type-A receptor 2 (EphA2) is responsible for the spread of cancerous cell in glioblastoma multiforme, but its active form inhibits abnormal cell growth and division 10 . Huntingtin interacting protein 1 (HIP1) is also reported in high level in brain cancer and is also correlated with the expression of EGFR 11 . The expression of HIP1 was found considerably elevated in tissue of primary brain tumour as compared to that in normal cortical brain tissue (63% versus 28%; P < 0.001) 11 .
Thyroid cancer
Thyroid cancer is one for which well-established diagnostic markers are not available 12 . Calcitonin is an anti-hypercalcemic hormone containing 32-amino acids, primarily produced by parafollicular cells of thyroid and is reported as a serum biomarker of medullary thyroid cancer (MTC). However, higher concentration of calcitonin is also reported in ageing, in C-cell hyperplasia, heavy weight, milk feeding, smoking, and small cell carcinoma of the lung with low incidence [13] [14] [15] . Serum thyroglobulin is reported as a biomarker for detecting thyroid cancer of follicular cell origin because it is not significantly detected after a total thyroidectomy 16, 17 . Galectin-3 could be another biomarker as it is overexpressed in thyroid carcinoma of follicular cell origin, whereas it is not significantly detected in normal thyroid tissues, goiters and follicular adenoma 18 .
Breast cancer
Breast cancer is one of the most predominant malignancies among female population in developed and developing countries. Breast cancer susceptible genes, BRCA1/2, play an important role in development of breast carcinoma. BRCA1 and BRCA2 are reported as tumour suppressor genes and mutation of these genes causes the development of premature truncated form, which was reported in malignant tumours 19 . For breast cancer, CA 15-3 and CEA are the most common diagnostic markers, but the sensitivity and specificity of CA15-3 and CEA is an issue with no correlation of concentrations of CA15-3 and CEA protein to disease progression 20, 21 . MUC1 gene product, MUC1/Y, has also been reported as a potential breast cancer marker and monoclonal antibody developed against MUC1/Y shows specific signals in breast cancer tissue 22 . ST3Gal-1 is a sialyl-transferase, responsible for sialylation of T antigen to Sialyl-T antigen. Antibodies against ST3Gal-1 show prominent and specific signals in sections of breast cancer tissue but not in fibroadenoma sections 23 . It is reported that p53 gene product is required for the integrity of non-tumourogenic phenotype of cells and tumour suppressor functions. MUC1 down-regulates p53 in breast cancer, which suggests its potential in breast cancer diagnosis 24 . Mammaglobin is another suggested biomarker for breast cancer with 76% sensitivity and 90% specificity 25 . There are several other biomarkers detected in breast cancer tissues. These include galectin-3, which was found to be correlated with disease progression 26 , survivin 27 , EGFR, ER and PR 28 , cytokeratin 19, cytokeratin 20, urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and small breast epithelial mucin (SBEM) 29, 30 . Maspin is reported as an inhibitor of serine proteases, having tumour suppressive activity in breast carcinoma and its expression decreases with tumour progression 31 . Human epidermal growth factor receptor 2 (HER2) is a protein found on the surface of normal breast cells. It is reported that some breast cancer cells have high expression of HER2, in such cases breast cancer is termed as HER2 positive breast cancer. Almost 15-25% of women are usually reported to have HER2 positive breast cancer 32, 33 . The identification of a new biomarker for breast cancer is still going on.
Lung cancer
Lung (bronchogenic) carcinoma is one of the most frequent cancers with a high mortality rate because of lack of early detection and thus, low cure rates. It is reported that only 1/7th of the patients is usually detected at an early stage with lung cancer 34 . It is also found that smoking is the main cause of lung cancer with smokers having a 10-fold greater risk to develop lung cancer than nonsmokers 35 . Small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two broad categories of lung cancer and of these, NSCLC accounts for more than 85% of lung cancer. NSCLC has further histological subtypes as adeno-carcinoma, squamous cell lung carcinoma and large cell carcinoma 36 . Several biomarkers have been studied and some show satisfactory results with each other rather than a single biomarker. Neuron-specific enolase (NSE), CYFRA 21-1, CEA and CA-125 are the most popular lung cancer biomarkers [35] [36] [37] . Neuron specific enolase (NSE) is an isomer of the glycolytic enzyme, enolase which is responsible for the development of phosphoenol pyruvate from phosphoglycerate.
It is present in neuroendocrine cells of brain tissue and neuroendocrine tumours. The concentration of NSE is frequently increased in SCLC patients as compared to NSCLC patients, thus being used to monitor the disease progression and management of SCLC 38 . Cytokeratin 19 fragment (CYFRA 21-1) is generally associated with SCLC type. The level of CYFRA 21-1 is generally linked with prognosis and disease response with sensitivity ranges between 23% and 70%, but it is also found in other respiratory diseases 39, 40 . CEA is oncofetal protein not expressed in normal condition in adults and it is involved in cell adhesion and cell signalling. De-repression of CEA gene causes large production of CEA in lung cancers 36 .
Esophageal cancer
Esophageal carcinoma is reported with recurrence at high rate with very poor prognosis due to late diagnosis and non-availability of a defined biomarker. CEA and squamous cell carcinoma antigen (SCCAg) are biomarkers generally used for esophageal carcinoma with CT scan biopsy. High level of SCCAg was linked with a reduced response to treatment and an increased possibility of recurrence of disease and death. Nonetheless, sensitivity and specificity in esophageal cancer still need satisfactory validation because of the presence of these markers in other cancer conditions 41, 42 .
Liver cancer
Hepatocellular carcinoma (HCC) is the fifth most common malignant condition and the third leading cause of cancer mortality 43 . High level of alpha-fetoprotein (AFP) is reported in HCC but increased levels are also reported in pregnancy and gastrointestinal cancers 44, 45 . It is reported that AFP concentrations in serum do not correlate with progression of HCC. Three different glycoforms of AFP are reported, i.e. AFP-L1, AFP-L2 and AFP-L3, on the basis of its binding capacity to lectin, lens culinaris agglutinin (LCA). It is reported that a high proportion of AFP-L3 is associated with poor differentiation, carcinogenic characteristics and malfunction of liver 46, 47 . Glypican-3 (GPC3), protein and its mRNA, is upregulated significantly in tumour tissues of HCC, confirmed by western blot, ELISA and immunohistochemical analysis. GPC3 is a membrane anchored heparin sulphate proteoglycan, which interacts with several growth factors and modulates their activities 48 . SCCAg is a serine protease inhibitor, which is produced at high level in the early stages of HCC 49 . Tumour associated glycoprotein 72 (TAG-72) and transforming growth factor-1 (TGF-1) are not only overproduced in HCC, but also produced significantly in other carcinomas. Their increased production is directly proportional to poor survival of patients with HCC. TAG-72 and TGF-1 could be potential prognostic markers for HCC 50, 51 .
Pancreatic cancer
Although pancreatic cancer accounts for only 3-4% of all types of cancers, the survival rate of patients is low 52 . The most common and validated marker for pancreatic cancer is CA19-9 with specificity of 70-98% and sensitivity of 70-90%. But the expression of CA19-9 is also significantly high in other types of digestive tract cancer 53 . The cancer antigen, CA-50, is defined by MAb of CA-50, which was developed against the COLO205 colorectal cancer cell line 54 . The sensitivity and specificity of CA-50 in serum is comparable to CA19-9 (ref 55) . Recently, glypican-1, a cell surface proteoglycan, is reported as a potential biomarker for diagnosis of cancer in pancreatic tissue at an early stage with high specificity and sensitivity, allowing to distinguishing the patients with early stage and late stage of pancreatic cancer from healthy subjects and benign tumour 56 .
Prostate cancer
The prostate specific antigen (PSA) is a kallikrein-like serine protease, the most studied biomarker for prostate cancer during the past two decades. PSA is secreted from prostate epithelial cells and responsible for liquefying human semen through its enzymatic action 57 . It is established that the serum level of PSA is a useful marker for prostate cancer along with rectal examination. Apart from prostate cancer, the amount of serum PSA is higher in other conditions, such as benign prostatic hypertrophy (BPH) and prostatitis, hence leading to false positive results 58 . Kattan et al. 59 studied more than 700 prostatectomy cases from a single institute and found that pretreatment plasma levels of interleukin-6 soluble receptor (IL6SR) and TGF-1 can be useful markers for predicting prostate cancer disease progression. They analysed more than 700 patients with stage cT1c to cT3a prostate cancer without any therapy for plasma concentration of TGF-1 and IL6SR. With the help of nomogram, they found that plasma concentration of TGF-1 and IL6SR improved the ability to predict biochemical progression by a prognostically considerable sideline 59 . Several other markers for prostate cancer are prostate specific membrane antigen, -methylacyl-coenzyme A racemase, hepsin, telomerase, d-catenin, a serine protease, TMPRSS2 and a prostatespecific non-coding RNA, PCA3. The potential of these markers alone or in combination with serum PSA is under study and needs to be validated for their utility as diagnostic or prognostic markers for prostate cancer [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] . CCL11 is a cytokine of CC chemokine family with 97 amino acid residues containing 23 amino acid signal peptide. CCL11 is reported for inducing chemotaxis and hence allergic responses. Multiplex ELISA assays were done to quantify protein concentration of various CCLs and IL-6 in the serum samples of males having <10 g/l of serum PSA. It was found that CCL11 serum concentration was elevated in prostate cancer patients. So, CCL11 could be a new biomarker for prostate cancer along with PSA 64 . Beta-micro-semino protein (MSMB) is also known as prostate secretory protein 94 (PSP94) encoded by MSMB gene in human and expressed in benign and malignant prostatic epithelium. Several reports suggested that expression level of MSMB was significantly high in tissue of prostate cancer patients and dropped significantly after radical prostatectomy. Further study is needed to validate MSMB as a diagnostic or prognostic biomarker for prostate cancer 65, 66 . Prostate cancer patients expressing high levels of MSMB which expressively reduced the risk for recurrence of disease after radical prostatectomy. They have demonstrated that MSMB is a prominent independent factor in prostate cancer, evaluating favourable outcome after radical prostatectomy 66 .
Colorectal cancer
Colorectal cancer is also known as rectal cancer, bowel cancer or colon cancer based on their origin. CEA is the most widely accepted tumour marker used for the diagnosis of colorectal cancer and the concentration of CEA is proportional to the progression of disease. About 53% of patients with involvement of regional lymph nodes have shown higher CEA concentration which decreased after radical surgery 67 . Along with CEA, CA19-9 is also reported in significant amount but both CEA and CA19-9 are also associated with other cancer conditions as pancreatic, gastric cancer and bladder cancer 68 . Cancer antigen, CA 72-4, is also reported as one of the promising markers for gastric cancer along with CEA and CA19-9 with an overall specificity of 95%, approximately 50% specificity in ovarian cancer and 40% specificity in colorectal and gastric cancer 69 . Midkine (MK or MDK), a nonglycosylated small protein, is a heparin-binding growth factor having two domains joint by S-S bridges. It is reported that MDK enhances the angiogenesis and proliferation of tumour cells. The increased expression of mRNA and protein of MDK have been found in various cancer types including colorectal, glioblastoma, thyroid carcinomas, liver, ovary, lung, esophageal, stomach, breast, prostate and bladder cancers 70, 71 .
Bladder cancer
There are several biomarkers described and others are under study for bladder cancer diagnosis. The bladder tumour antigen (BTA) assay is easy and one-step immunochromatographic assay for the detection of bladder tumour associated antigen in urine with 66% specificity 72 . FDA has approved bladder tumour antigen and nuclear matrix protein 22 (NMP22) assays for diagnosis and prognosis of bladder cancer. However, BTA is not very efficient to replace urine cytology in detecting tumours in bladder because of false-positive results 73 . Other biomarkers are survivin, BLCA-4, CYFRA 21-1 and DD23 but need validation for diagnostic potential in bladder cancer 74 .
Ovarian cancer
Cancer antigen 125 (CA-125) is the most extensively studied protein marker for screening of ovarian cancer. It has been proved to identify malignancy in ovarian tissue before the beginning of clinical symptoms. However, higher levels of CA-125 are also observed in patients with other gynecological disorders (e.g. polycystic ovarian disorder), other cancer conditions and in healthy women during menstruation (>300 KU/L) which gives high false-positive results 75, 76 . Elevated concentration of antibodies against Her2/neu at early and late stage and antibodies against p53 at late stage have been reported in ovarian cancer patients. Hence, these antibodies may provide a more consistent serum marker for ovarian cancer 77, 78 . Several biomarkers for ovarian cancer at the early stage are osteopontin, HE4, B7-H4, prostasin, vascular endothelial growth factor, mesothelin, interleukin-6, interleukin-8, eosinophil-derived neurotoxin and COOHosteopontin fragments, OVX1, lysophosphatidic acid (LPA), apo-lipoprotein A1 (APOA1), transthyretin, BRCA1, RASSF1A, insulin like growth factor binding protein 3 (IGFBP-3). Biomarkers for ovarian cancer at late stage are haptoglobin, osteopontin, mesothelin, B7-H4, HE4, prostasin, macrophage colony stimulating factor (M-CSF), vascular endothelial growth factor (VEGF), LPA, BRCA1, Sat2-Chr1, Sat, RASSF1A, IGFBP-3 (ref. 79) . Since the last decade, there have been several promising biomarkers evaluated for ovarian cancer. These have been evaluated either alone or in combination with each other for sensitivity and specificity. The study demonstrated that HE4 has highest sensitivity at 72.9% with 95% specificity. Evaluation results suggest that CA-125 and HE4 together have a greater sensitivity (76.4%) with 95% specificity 80 .
Melanoma
Melanoma is reported as the most aggressive form of skin carcinoma which begins in the melanin-forming cells of skin. Tumour-associated antigen 90 (TA-90) was first reported in the serum and urine of metastatic melanoma patients. At early stages, TA-90 is abundant as circulating immune complexes (ICs), which can be quantified by ELISA. Several studies demonstrate that TA90-IC is a sensitive and specific marker of re-appearance of malignant melanoma in patients and it is also associated with poor survival 81 .
Kelley et al. 82 demonstrated that TA-90 is the first biomarker that predicts subclinical metastatic disease (in 76% of reported patients) and survival for patients at early stage of melanoma with 77% and 76% sensitivity and specificity respectively. S-100 protein, member of S100 family, has been reported as a promising serological biomarker and prognostic marker of melanoma metastases by immunohistochemistry and is currently being used as a routine biomarker for detection of melanoma [83] [84] [85] . By luminometric immunoassay analysis, it was found that 79% of patients have shown elevated S-100 whereas NSE was significantly elevated in 42% patients 85 . A mature melanoma-inhibitory activity factor (MIA), a 107 amino acid protein, is also reported as one of the promising biomarkers for metastatic melanoma at late stage with higher sensitivity and specificity and it is not reported in melanocytes and normal skin. Melanomainhibitory activity was identified in the supernatant fraction of culture of metastatic melanoma cell line, which functions as inhibitory factor of a melanoma progression. It is found that high serum concentration of MIA protein and its mRNA expression is directly proportional to the degree of metastasis in melanoma patient 86, 87 .
Lymphoma
Lymphoma is a common term used for cancer of lymphocytes. The WHO categorizes lymphoid neoplasms into 3 groups -B-cell, T/NK cell neoplasms and Hodgkin's lymphoma 88 . The most significant biomarkers for lymphoma are beta-2-microglobulin (B2M) and lactate dehydrogenase (LDH). It is reported that B2M increases with increased production and destruction of cells. On the basis of several findings it is assumed that increased serum concentration of B2M is directly linked with advancement of disease stage, higher lactate, LDH and greater tumour burden 89 . LDH is another biomarker reported in patients with non-Hodgkin's lymphoma. It is generally present in almost all cells of the body and released after cell damage. LDH is generally used for monitoring of patients with advanced lymphoma but the presence of LDH is non-specific 90 .
Leukemia
Leukemia, also called blood cancer, is a heterogeneous disease starting from bone marrow. Leukemia can be classified into acute and chronic myeloid leukemia. Acute myeloid leukemia (AML) is a condition in which bone marrow makes huge numbers of abnormal immature WBC (blast) derived from a myeloid stem cell 91 . Different studies demonstrate that RAS (Renin-angiotensin system) component, renin, is expressed in the microenvironment of bone marrow as well as in hematopoietic cells. Bone marrow blast cells of some types of AML produce renin in high amount while no expression was found in bone marrow of normal person [92] [93] [94] . The concentration of renin and angiotensin converting enzyme (ACE) was analysed in bone marrow (BM) aspirates along with blood samples. It was found that the concentration of ACE (38  6.2 U/l) in BM is ominously higher than blood samples (29.5  5.3 U/l) whereas concentration of renin in BM is slightly lower (18.6  6.2 U/l) than blood sample (21.3  8.3 U/l). In control samples the values were significantly lower 92 . Other reported potential biomarkers are core binding factor (CBF), retinoic acid receptor  (RAR), and c-KIT for diagnosis of leukemia 95 . 
Conclusion
There are several factors in the development of various types of cancer. So, along with mechanical tools, a combination of diagnostic markers could be a useful platform to understand the disease progression and patient prognosis. Few markers are found very specific, such as PSA for prostate cancer, CA15-3 for breast cancer, HE4 for ovarian cancer, etc. But most of the tumour markers involved in several cancers includes CEA, NSE, galectin-3, midkine, B2M, CA125, CA72-4, CA19-9, CRP, AFP, etc. Although PSA is routinely used for the profiling of prostate cancer patient, its sensitivity and specificity is always a concern. CA15-3 is used for the diagnosis of breast cancer, but in some cases, clinicians have failed to correlate the expression level and aberrant glycosylation with disease progression. HE4 is one for the new emerging biomarker for ovarian cancer, but still needs to be validated with disease progression. Serum diagnostic markers may help for accurate cancer diagnosis and prognosis. However, there is still a need to exploit the potential of these markers.
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